
-
Cluster bombs kill, wound over 1,200 in Ukraine since 2022: monitor
-
Most Asian markets drop ahead of expected US rate cut
-
Australia, Papua New Guinea to sign 'historic' defence deal
-
Myanmar junta says no voting in dozens of constituencies
-
Rubio to discuss Qatar aftermath, Gaza with Netanyahu
-
Chinese factory, consumer activity slow amid economy struggles
-
US cuts leave Zimbabwe sex workers scrambling for alternatives
-
Alonso's Real Madrid revitalised for new Champions League mission
-
Arsenal eye Champions League charge with revamped attack
-
'No regrets': wounded Nepali protesters proud at change
-
Key Emmys moments: Children, Colbert, women and politics
-
'No regrets': wounded Nepalis protesters proud at change
-
'Adolescence,' 'The Studio' dominate television's Emmy Awards
-
WTO fishing deal: the net results
-
Malaysia's largest island state aims to be region's 'green battery'
-
Philippines president says corruption scandal protests justified
-
Asian markets fluctuate ahead of expected US rate cut
-
UK aristocrat, partner face jail over baby daughter's death
-
Japan and Fiji cruise into Pacific Nations Cup rugby final rematch
-
As King Charles hosts Trump, what do UK state visits entail?
-
First-ever Tanzanian gold as Simbu dips past Petros in world marathon
-
100 days later, US federal workers navigate post-Musk wreckage
-
Rising oceans to threaten 1.5 million Australians by 2050: report
-
Kipyegon bids for fourth 1500m world gold, Wanyonyi in loaded 800m
-
'The Studio,' 'Severance' and 'Adolescence' among Emmy winners
-
Trump and King Charles: heads of state with opposing personalities
-
Scheffler surges to PGA Procore victory in Ryder Cup warm-up
-
Bloody Sunday trial of British ex-soldier to open in Belfast
-
Trump heads for historic second UK state visit
-
Turkey court tries case that could oust opposition leadership
-
Simbu dips past Petros for world marathon gold
-
Mexico's macabre Island of the Dolls inspires Tim Burton and Lady Gaga
-
Television stars shine bright on Emmys red carpet
-
'The Studio' claims early win as TV's Emmys kick off
-
Japan rips Tonga to reach Pacific Nations Cup rugby final
-
Australia's ANZ bank hit with record fine over 'widespread misconduct'
-
Eagles top Chiefs in Super Bowl rematch as Cowboys edge Giants in NFL thriller
-
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
-
Genflow Signs CDAs with Animal Health Companies
-
HyProMag USA Project Update for Its Rare Earth Magnet Recycling and Manufacturing Plants in The United States
-
Liberty Supports Women-Led Businesses with Flexible Business Loan Solutions
-
Seattle's Raleigh hits 54th homer of season for MLB marks
-
NFL Cowboys top Giants in overtime while Lions maul Bears
-
Trump concerned S. Korean arrests could 'frighten' investors
-
Timeless Modric opens AC Milan account with winner against Bologna
-
Spring quick-fire hat-trick helps Racing stun Bordeaux-Begles
-
Macau's first 'patriots' election sees low turnout
-
Prince Harry says has 'clear conscience' over explosive memoir
-
Modric opens AC Milan account with winner against Bologna
-
Schroeder seals Euro basketball title for world champions Germany

Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their families by developing truly transformational and highly disease-specific immunotherapies that are potentially curative. Barinthus Bio's pipeline for I&I indications is enabled by our proprietary and highly differentiated platform for promoting immune tolerance, SNAP-TI, that is designed to guide a patient's T cells to a specific location to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease and is currently in a Phase 1 clinical trial. Barinthus Bio's differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with autoimmune and inflammatory diseases. For more information, visit www.barinthusbio.com.
Event: Q2 Investor Summit
Presentation Time: June 10, 11:00 - 11:30 AM ET
Location: WEBCAST LINK
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who have a near-term catalyst and are undervalued.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
AccessNewswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESSWIRE
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Investor Summit Group
View the original press release on ACCESS Newswire
P.Stevenson--AMWN